Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth - Research and Markets

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/zpf9dx/prostate_cancer) has announced the addition of the "Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth" report to their offering.

Prostate Cancer (PC) is a disease predominately of the elderly with 60% of cases diagnosed in men aged 65 or over. Prostate cancer is slow growing, and asymptomatic at its earliest stages. However, with the use of digital rectal examination, the PSA test, and the incidental discovery of tumors following resection of the prostate, the majority of PC cases are diagnosed at an early stage (60%).

As PC is slow growing, many patients can leave their disease untreated for extended periods of time with frequent monitoring (watchful waiting or active surveillance), with many patients dying from other causes before treatment is indicated. Surgery and/or radiotherapy is often curative when treatment is indicated for localized disease, with androgen deprivation being the standard of first-line care.

However, most patients ultimately develop resistant disease, for whom treatment options have historically been limited, with treatment with docetaxel being standard. The recent approval of Zytiga and Xtandi for docetaxel refractory disease in 2011 and 2012 have improved survival of resistant patients, but there is a clear clinical need to diversify the treatment options for this patient cohort.

The current late-stage drugs in development for PC address this clinical need, however, results so far have been mixed, with none demonstrating clinically transformative efficacy of safety. As a result, the growth in PC prevalence as a result of a global aging population is expected to be the key driver of this market throughout the forecast period.

Key Topics Covered:

1 Tables & Figures

2 Introduction

2.1 Disease Introduction

2.2 Symptoms and Risk Factors

2.3 Etiology and Pathophysiology

2.4 Diagnosis

2.4.1 Digital Rectal Examination

2.4.2 Imaging

2.4.3 Biopsy

2.4.4 Tumor Markers

2.5 Disease Staging and Risk Assessment

2.6 Treatment Algorithm

2.6.1 Localized or Locally Advanced Prostate Cancer

2.6.2 Hormone Sensitive Metastatic Prostate Cancer

2.6.3 Metastatic Castration Resistant Prostate Cancer

2.6.4 Heat Map - Marketed Products Overview

3 Marketed Products

3.1 Hormonal Therapies

3.1.1 First Generation

3.1.2 Second Generation

3.2 Chemotherapy Agents

3.2.1 Taxotere (docetaxel) - Sanofi

3.2.2 Jevtana (cabazitaxel) - Sanofi

3.3 Therapeutic Vaccines

3.3.1 Provenge (sipuleucel-t) - Dendreon

3.4 Bone Metastasis Treatments

3.4.1 Xofigo (radium 223) - Bayer/Algeta

3.4.2 Xgeva (denosumab) - Amgen

3.4.3 Zometa (zoledronic acid) - Novartis

4 Pipeline Product Developments

4.1 Developmental Pipeline by Phase and Molecular Target

4.2 Mechanisms of Action in the Pipeline

5 Clinical Trials

5.1 Clinical Trial Failure Rate

5.2 Clinical Trial Duration

5.2.1 Clinical Trial Size

5.3 Promising Pipeline Molecules

5.3.1 Localized Disease

5.3.2 mCRPC - First Line

5.3.3 mCRPC - Second Line

6 Market Forecasts

7 Drivers and Barriers

7.1 Market Drivers

7.1.1 Major Unmet Treatment Needs of Late-Stage PC Patients

7.1.2 Increasing Incidence of PC Driven by Global Aging of Population

7.1.3 Continued Uptake of Zytiga and Xtandi

7.1.4 Approval of Numerous Premium Products in PC Market

7.1.5 High Number of Pipeline Drugs

7.2 Market Barriers

7.2.1 Recent and Future Patent Expiries

7.2.2 Uptake Limited by Premium Price of Several Novel Therapies

8 Strategic Consolidation

8.1 Co-development Deals

8.1.1 Pfizer Enters into Co-Development Agreement with Merck

8.1.2 Immatics Enters into R&D Agreement with Roche for Cancer Vaccine

8.1.3 Merck & Co Enters into Agreement with ARIAD Pharma

8.1.4 Medivation Enters into Co-Development Agreement with Astellas Pharma

8.1.5 Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products

8.1.6 Bayer Schering Enters into Co-Development Agreement with Micromet

8.1.7 Takeda Pharma Enters into Agreement with Cell Genesys

8.2 Licensing Deals

8.2.1 Astellas Pharma Enters into Licensing Agreement with AVEO Pharma for Tivozanib

8.2.2 Algeta Enters into Licensing Agreement with Bayer for Alpharadin

8.2.3 Sanofi-Aventis Enters into Licensing Agreement with Oxford BioMedica

8.2.4 Ascenta Therapeutics Enters into Licensing Agreement with Sanofi

8.2.5 Aduro Biotech Enters into Exclusive Licensing Agreement with Janssen Biotech

9 Appendix

For more information visit http://www.researchandmarkets.com/research/zpf9dx/prostate_cancer

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Prostate Cancer

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Prostate Cancer